To test or not to test? An evidence-based assessment of the value of screening and monitoring tests when using systemic biologic agents to treat psoriasis

Journal of the American Academy of Dermatology

Volumn 58, Issue 6, 2008, Pages 970-977

  Huang, William ^a   Cordoro, Kelly M ^b   Taylor, Sarah L ^a   Feldman, Steven R ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALEFACEPT; EFALIZUMAB; ETANERCEPT; INFLIXIMAB;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE SEVERITY; DRUG INHIBITION; DRUG SCREENING; EVIDENCE BASED PRACTICE; FOOD AND DRUG ADMINISTRATION; HUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SCREENING TEST; THROMBOCYTOPENIA;

BIOLOGICAL THERAPY; DIAGNOSTIC TESTS, ROUTINE; EVIDENCE-BASED MEDICINE; HUMANS; PSORIASIS;

EID: 43249114046     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2008.03.004     Document Type: Article

References (84)

1. US Preventive Services Task Force. Methods and background (2007), Agency for Healthcare Research and Quality, Rockville (MD)
2. Gordon K.B., Vaishnaw A.K., O'Gorman J., Haney J., and Menter A. Treatment of psoriasis with alefacept: correlation of clinical improvement with reductions of memory T-cell counts. Arch Dermatol 139 (2003) 1563-1570
3. Ortonne J.P., Lebwohl M., and Em G.C. Alefacept-induced decreases in circulating blood lymphocyte counts correlate with clinical response in patients with chronic plaque psoriasis. Eur J Dermatol 13 (2003) 117-123
4. Krueger G.G., Papp K.A., Stough D.B., Loven K.H., Gulliver W.P., and Ellis C.N. A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol 47 (2002) 821-833
5. Lebwohl M., Christophers E., Langley R., Ortonne J.P., Roberts J., and Griffiths C.E. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol 139 (2003) 719-727
6. Ellis C.N., and Krueger G.G. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 345 (2001) 248-255
7. Gribetz C.H., Blum R., Brady C., Cohen S., and Lebwohl M. An extended 16-week course of alefacept in the treatment of chronic plaque psoriasis. J Am Acad Dermatol 53 (2005) 73-75
8. Efalizumab (Raptiva). [package insert] (2005), Genentech I, San Francisco (CA)
9. Infliximab (Remicade). [package insert] (2006), Centocor I, Malvern (PA)
10. Kraan M.C., van Kuijk A.W., Dinant H.J., Goedkoop A.Y., Smeets T.J., de Rie M.A., et al. Alefacept treatment in psoriatic arthritis: reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis. Arthritis Rheum 46 (2002) 2776-2784
11. Mease P.J., Gladman D.D., and Keystone E.C. Alefacept in combination with methotrexate for the treatment of psoriatic arthritis: results of a randomized, double-blind, placebo-controlled study. Arthritis Rheum 54 (2006) 1638-1645
12. Lowe N.J., Gonzalez J., Bagel J., Caro I., Ellis C.N., and Menter A. Repeat courses of intravenous alefacept in patients with chronic plaque psoriasis provide consistent safety and efficacy. Int J Dermatol 42 (2003) 224-230
13. Menter A., Cather J.C., Baker D., Farber H.F., Lebwohl M., and Darif M. The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis. J Am Acad Dermatol 54 (2006) 61-63
14. Alefacept (Amevive). [package insert] (2005), Biogen I, Cambridge (MA)
15. Goffe B., Papp K., Gratton D., Krueger G.G., Darif M., Lee S., et al. An integrated analysis of thirteen trials summarizing the long-term safety of alefacept in psoriasis patients who have received up to nine courses of therapy. Clin Ther 27 (2005) 1912-1921
16. Thaci D., Patzold S., Kaufmann R., and Boehncke W.H. Treatment of psoriasis with alefacept in patients with hepatitis C infection: a report of two cases. Br J Dermatol 152 (2005) 1048-1050
17. Dubertret L., Sterry W., Bos J.D., Chimenti S., Shumack S., Larsen C.G., et al. Clinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial. Br J Dermatol 155 (2006) 170-181
18. Gordon K.B., Papp K.A., Hamilton T.K., Walicke P.A., Dummer W., Li N., et al. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA 290 (2003) 3073-3080
19. Gottlieb A.B., Hamilton T., Caro I., Kwon P., Compton P.G., and Leonardi C.L. Long-term continuous efalizumab therapy in patients with moderate to severe chronic plaque psoriasis: updated results from an ongoing trial. J Am Acad Dermatol 54 Suppl (2006) S154-S163
20. Lebwohl M., Tyring S.K., Hamilton T.K., Toth D., Glazer S., Tawfik N.H., et al. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 349 (2003) 2004-2013
21. Leonardi C.L., Papp K.A., Gordon K.B., Menter A., Feldman S.R., Caro I., et al. Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial. J Am Acad Dermatol 52 (2005) 425-433
22. Menter A., Gordon K., Carey W., Hamilton T., Glazer S., Caro I., et al. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. Arch Dermatol 141 (2005) 31-38
23. Papp K.A., Bressinck R., Fretzin S., Goffe B., Kempers S., Gordon K.B., et al. Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: a phase IIIb, randomized, controlled trial. Int J Dermatol 45 (2006) 605-614
24. Papp K.A., Miller B., Gordon K.B., Caro I., Kwon P., Compton P.G., et al. Efalizumab retreatment in patients with moderate to severe chronic plaque psoriasis. J Am Acad Dermatol 54 Suppl (2006) S164-S170
25. Papp K.A., Camisa C., Stone S.P., Caro I., Wang X., Compton P., et al. Safety of efalizumab in patients with moderate to severe chronic plaque psoriasis: review of clinical data, part II. J Cutan Med Surg 9 (2005) 313-323
26. Mease P.J., Goffe B.S., Metz J., VanderStoep A., Finck B., and Burge D.J. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomized trial. Lancet 356 (2000) 385-390
27. Mease P.J., Kivitz A.J., Burch F.X., Siegel E.L., Cohen S.B., Ory P., et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 50 (2004) 2264-2272
28. Mease P.J., Kivitz A.J., Burch F.X., Siegel E.L., Cohen S.B., Ory P., et al. Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept. J Rheumatol 33 (2006) 712-721
29. de Vlam K., and Lories R.J. Efficacy, effectiveness and safety of etanercept in monotherapy for refractory psoriatic arthritis: a 26-week observational study. Rheumatology (Oxford) 45 (2006) 321-324
30. Gottlieb A.B., Matheson R.T., Lowe N., Krueger G.G., Kang S., Goffe B.S., et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 139 (2003) 1627-1632
31. Krueger G.G., Elewski B., Papp K., Wang A., Zitnik R., and Jahreis A. Patients with psoriasis respond to continuous open-label etanercept treatment after initial incomplete response in a randomized, placebo-controlled trial. J Am Acad Dermatol 54 Suppl (2006) S112-S119
32. Leonardi C.L., Powers J.L., Matheson R.T., Goffe B.S., Zitnik R., Wang A., et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 349 (2003) 2014-2022
33. Papp K.A., Tyring S., Lahfa M., Prinz J., Griffiths C.E., Nakanishi A.M., et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 152 (2005) 1304-1312
34. Gottlieb A.B., Leonardi C.L., Goffe B.S., Ortonne J.P., van der Kerkhof P.C., Zitnik R., et al. Etanercept monotherapy in patients with psoriasis: a summary of safety, based on an integrated multistudy database. J Am Acad Dermatol 54 Suppl (2006) S92-S100
35. Tyring S., Gottlieb A., Papp K., Gordon K., Leonardi C., Wang A., et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomized phase III trial. Lancet 367 (2006) 29-35
36. Costanzo A., Mazzotta A., Papoutsaki M., Nistico S., and Chimenti S. Safety and efficacy study on etanercept in patients with plaque psoriasis. Br J Dermatol 152 (2005) 187-189
37. Etanercept (Enbrel). [package insert] (2003), Amgen/Wyeth Pharmaceuticals, Thousand Oaks (CA)
38. Bissonnette R. Etanercept for the treatment of psoriasis. Skin Therapy Lett 11 (2006) 1-4
39. De S.C., Paradisi A., Capizzi R., Carbone A., Siciliano M., and Amerio P.L. Etanercept therapy in two patients with psoriasis and concomitant hepatitis C. J Am Acad Dermatol 54 (2006) 1102-1104
40. Magliocco M.A., and Gottlieb A.B. Etanercept therapy for patients with psoriatic arthritis and concurrent hepatitis C virus infection: report of 3 cases. J Am Acad Dermatol 51 (2004) 580-584
41. Rokhsar C., Rabhan N., and Cohen S.R. Etanercept monotherapy for a patient with psoriasis, psoriatic arthritis, and concomitant hepatitis C infection. J Am Acad Dermatol 54 (2006) 361-362
42. Marotte H., Fontanges E., Bailly F., Zoulim F., Trepo C., and Miossec P. Etanercept treatment for three months is safe in patients with rheumatological manifestations associated with hepatitis C virus. Rheumatology (Oxford) 46 (2007) 97-99
43. Ting P.T., and Koo J.Y. Use of etanercept in human immunodeficiency virus (HIV) and acquired immunodeficiency syndrome (AIDS) patients. Int J Dermatol 45 (2006) 689-692
44. Antoni C., Dechant C., Hanns-Martin Lorenz P.D., Wendler J., Ogilvie A., Lueftl M., et al. Open-label study of infliximab treatment for psoriatic arthritis: clinical and magnetic resonance imaging measurements of reduction of inflammation. Arthritis Rheum 47 (2002) 506-512
45. Cauza E., Spak M., Cauza K., Hanusch-Enserer U., Dunky A., and Wagner E. Treatment of psoriatic arthritis and psoriasis vulgaris with the tumor necrosis factor inhibitor infliximab. Rheumatol Int 22 (2002) 227-232
46. Feletar M., Brockbank J.E., Schentag C.T., Lapp V., and Gladman D.D. Treatment of refractory psoriatic arthritis with infliximab: a 12 month observational study of 16 patients. Ann Rheum Dis 63 (2004) 156-161
47. Provenzano G., Termini A., Le M.C., and Rinaldi F. Efficacy of infliximab in psoriatic arthritis resistant to treatment with disease modifying antirheumatic drugs: an open pilot study. Ann Rheum Dis 62 (2003) 680-681
48. Salvarani C., Cantini F., Olivieri I., Macchioni P., Padula A., Niccoli L., et al. Efficacy of infliximab in resistant psoriatic arthritis. Arthritis Rheum 49 (2003) 541-545
49. Yazdani-Biuki B., Wohlfahrt K., Mulabecirovic A., Mueller T., Hermann J., Graninger W.B., et al. Long term treatment of psoriatic arthritis with infliximab. Ann Rheum Dis 63 (2004) 1531-1532
50. Antoni C., Krueger G.G., de Vlam K., Birbara K., Beutler A., Guzzo C., et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 64 (2005) 1150-1157
51. Antoni C.E., Kavanaugh A., Kirkham B., Tutuncu Z., Burmester G.R., Schneider U., et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 52 (2005) 1227-1236
52. Cassano N., Loconsole F., Amoruso A., Coviello C., Filieri M., Filotico R., et al. Infliximab monotherapy for refractory psoriasis: preliminary results. Int J Immunopathol Pharmacol 17 (2004) 373-380
53. Chan J.J., and Gebauer K. Treatment of severe recalcitrant plaque psoriasis with single-dose intravenous tumor necrosis factor-alpha antibody (infliximab). Australas J Dermatol 44 (2003) 116-120
54. Chaudhari U., Romano P., Mulcahy L.D., Dooley L.T., Baker D.G., and Gottlieb A.B. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomized trial. Lancet 357 (2001) 1842-1847
55. Gottlieb A.B., Evans R., Li S., Dooley L.T., Guzzo C.A., Baker D., et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 51 (2004) 534-542
56. Kalb R.E., and Gurske J. Infliximab for the treatment of psoriasis: clinical experience at the State University of New York at Buffalo. J Am Acad Dermatol 53 (2005) 616-622
57. Krathen R.A., Berthelot C.N., and Hsu S. Sustained efficacy and safety of infliximab in psoriasis: a retrospective study of 73 patients. J Drugs Dermatol 5 (2006) 251-254
58. Reich K., Nestle F.O., Papp K., Ortonne J.P., Evans R., Guzzo C., et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicenter, double-blind trial. Lancet 366 (2005) 1367-1374
59. Reich K., Nestle F.O., Papp K., Ortonne J.P., Wu Y., Bala M., et al. Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial. Br J Dermatol 154 (2006) 1161-1168
60. Schopf R.E., Aust H., and Knop J. Treatment of psoriasis with the chimeric monoclonal antibody against tumor necrosis factor alpha, infliximab. J Am Acad Dermatol 46 (2002) 886-891
61. Smith C.H., Jackson K., Bashir S.J., Perez A., Chew A.L., Powell A.M., et al. Infliximab for severe, treatment-resistant psoriasis: a prospective, open-label study. Br J Dermatol 155 (2006) 160-169
62. Keane J., Gershon S., Wise R.P., Mirabile-Levens E., Kasznica J., Schwieterman W.D., et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345 (2001) 1098-1104
63. Campbell S., and Ghosh S. Infliximab therapy for Crohn's disease in the presence of chronic hepatitis C infection. Eur J Gastroenterol Hepatol 13 (2001) 191-192
64. del Valle García-Sánchez M., Gomez-Camacho F., Poyato-Gonzalez A., Iglesias-Flores E.M., de Dios-Vega J.F., and Sancho-Zapatero R. Infliximab therapy in a patient with Crohn's disease and chronic hepatitis B virus infection. Inflamm Bowel Dis 10 (2004) 701-702
65. Esteve M., Saro C., Gonzalez-Huix F., Suarez F., Forne M., and Viver J.M. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut 53 (2004) 1363-1365
66. Magro F., Pereira P., Carneiro F., and Veloso F.T. Reactive hepatitis in a patient with Crohn's disease successfully treated with infliximab: does tumor necrosis factor alpha play a role in reactive hepatitis?. Inflamm Bowel Dis 11 (2005) 88-90
67. Michel M., Duvoux C., Hezode C., and Cherqui D. Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset still's disease. J Rheumatol 30 (2003) 1624-1625
68. Millonig G., Kern M., Ludwiczek O., Nachbaur K., and Vogel W. Subfulminant hepatitis B after infliximab in Crohn's disease: need for HBV-screening?. World J Gastroenterol 12 (2006) 974-976
69. Oniankitan O., Duvoux C., Challine D., Mallat A., Chevalier X., Pawlotsky J.M., et al. Infliximab therapy for rheumatic diseases in patients with chronic hepatitis B or C. J Rheumatol 31 (2004) 107-109
70. Ostuni P., Botsios C., Punzi L., Sfriso P., and Todesco S. Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate. Ann Rheum Dis 62 (2003) 686-687
71. Peterson J.R., Hsu F.C., Simkin P.A., and Wener M.H. Effect of tumor necrosis factor alpha antagonists on serum transaminases and viremia in patients with rheumatoid arthritis and chronic hepatitis C infection. Ann Rheum Dis 62 (2003) 1078-1082
72. Roux C.H., Brocq O., Breuil V., Albert C., and Euller-Ziegler L. Safety of anti-TNF-alpha therapy in rheumatoid arthritis and spondylarthropathies with concurrent B or C chronic hepatitis. Rheumatology (Oxford) 45 (2006) 1294-1297
73. Ueno Y., Tanaka S., Shimamoto M., Miyanaka Y., Hiyama T., Ito M., et al. Infliximab therapy for Crohn's disease in a patient with chronic hepatitis B. Dig Dis Sci 50 (2005) 163-166
74. Wendling D., Auge B., Bettinger D., Lohse A., Le H.G., Bresson-Hadni S., et al. Reactivation of a latent precore mutant hepatitis B virus related chronic hepatitis during infliximab treatment for severe spondyloarthropathy. Ann Rheum Dis 64 (2005) 788-789
75. Bartke U., Venten I., Kreuter A., Gubbay S., Altmeyer P., and Brockmeyer N.H. Human immunodeficiency virus-associated psoriasis and psoriatic arthritis treated with infliximab. Br J Dermatol 150 (2004) 784-786
76. Gaylis N. Infliximab in the treatment of an HIV positive patient with Reiter's syndrome. J Rheumatol 30 (2003) 407-411
77. Mease P.J., Gladman D.D., Ritchlin C.T., Ruderman E.M., Steinfeld S.D., Choy E.H., et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 52 (2005) 3279-3289
78. Adalimumab (Humira). [package insert] (2004), Abbott Laboratories, North Chicago (IL)
79. Gordon K.B., Langley R.G., Leonardi C., Toth D., Menter M.A., Kang S., et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol 55 (2006) 598-606
80. Furst D.E., Schiff M.H., Fleischmann R.M., Strand V., Birbara C.A., Compagnone D., et al. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (safety trial of adalimumab in rheumatoid arthritis). J Rheumatol 30 (2003) 2563-2571
81. Weinblatt M.E., Keystone E.C., Furst D.E., Moreland L.W., Weisman M.H., Birbara C.A., et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 48 (2003) 35-45
82. Sterry W., Barker J., Boehncke W.H., Bos J.D., Chimenti S., Christophers E., et al. Biological therapies in the systemic management of psoriasis: international consensus conference. Br J Dermatol 151 Suppl (2004) 3-17
83. Routhouska S.B., and Korman N.J. Initiating and monitoring patients on biologic therapy for psoriasis beyond the FDA: our more cautious approach. Psoriasis Forum. J Nat Psoriasis Found 12 (2006) 12-15
84. Smith C.H., Anstey A.V., Barker J.N., Burden A.D., Chalmers R.J., Chandler D., et al. British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005. Br J Dermatol 153 (2005) 486-497